menu

Genesis Pharma

The Greek pharmaceutical company that invests in global innovation for more than two decades

GENESIS Pharma was one of the first pharmaceutical companies in Europe to specialize in the promotion, sales and distribution of biopharmaceutical products and is currently the largest by turnover among Greek companies focusing on innovative medicines.

Through long-standing strategic partnerships with some of the leading global pharmaceutical companies committed to cutting-edge R&D, GENESIS Pharma has created a strong portfolio of innovative and high therapeutic value pharmaceutical products for more than 30 severe and rare diseases.

Mr. Konstantinos Evripides, CEO

CEO Message

“We are a Greek pharmaceutical company established with the vision to offer a better quality of life to thousands of patients living with threatening and rare diseases through innovative treatments. It is a purpose that creates a special sense of responsibility and shapes the overall ‘personality’ of the company.

What we seek is to be a model company overall, to grow and operate as a positive member in our market and the society at large, creating value for our company, but also for those around us.

Our choice for growth is based on the values of responsibility, integrity, quality and added value for the medical community and patients, our people and our international partners. These values are an integral part of our strategy, but also of the corporate goals and procedures based on which we operate daily, since it is important to be put into practice by all of us at GENESIS Pharma.

At the same time, we are constantly strengthening our social contribution, which does not only include health and prevention activities, but also extends to social issues that we consider very important and concern equal opportunities and education of children, as well as the support of vulnerable social groups.

Overall, our contribution in the national economy and society exceeds 30% of our annual turnover. What we aim is for our commitments and the actions we undertake to have continuity in time, but also to strengthen our investment as our company grows”.


Mr. Konstantinos Evripides, CEO

Organization in numbers

Open

Initiatives

Responsible Entrepreneurship